Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
MW33 injection
COMBINATION_PRODUCT
2 trials
Sponsors
Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions
Covid19
Phase 1
A Clinical Study to Evaluate MW33 Injection
Completed
NCT04533048
Mabwell (Shanghai) Bioscience Co., Ltd.
Covid19
Start: 2020-08-07
End: 2020-12-02
Updated: 2021-02-26
Phase 2
A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19
NCT04627584
Mabwell (Shanghai) Bioscience Co., Ltd.
Covid19
Start: 2020-12-29
End: 2021-09-30
Target: 150
Updated: 2021-02-26
Related Papers
Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody
Emerging Microbes & Infections
2021-01-01
13 citations